Journal
ANNALS OF ONCOLOGY
Volume 26, Issue 12, Pages 2375-2391Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdv383
Keywords
immune checkpoint antibody; anti-PD-1; anti-PD-L1; toxicity; adverse event
Categories
Funding
- NCI NIH HHS [P30 CA008748] Funding Source: Medline
Ask authors/readers for more resources
Most adverse events with anti-programmed-cell-death protein 1 (PD-1)/PD-L1 agents are generally mild and reversible, yet some high-grade immune-related adverse events are managed with corticosteroids and other immune-modulating agents. The mechanisms underlying the development of these toxicities are the subject of ongoing studies.Immune checkpoint antibodies that augment the programmed cell death protein 1 (PD-1)/PD-L1 pathway have demonstrated antitumor activity across multiple malignancies, and gained recent regulatory approval as single-agent therapy for the treatment of metastatic malignant melanoma and nonsmall-cell lung cancer. Knowledge of toxicities associated with PD-1/PD-L1 blockade, as well as effective management algorithms for these toxicities, is pivotal in order to optimize clinical efficacy and safety. In this article, we review selected published and presented clinical studies investigating single-agent anti-PD-1/PD-L1 therapy and trials of combination approaches with other standard anticancer therapies, in multiple tumor types. We summarize the key adverse events reported in these studies and their management algorithms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available